Minimally Invasive Pediatric VAD for Treatment of Acute Heart Failure

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$199,454.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1R44HL099192-01
Award Id:
96323
Agency Tracking Number:
HL099192
Solicitation Year:
n/a
Solicitation Topic Code:
NHLBI
Solicitation Number:
n/a
Small Business Information
ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS, MA, 01923
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
050636737
Principal Investigator:
SCOTTCORBETT
(978) 646-1684
SCORBETT@ABIOMED.COM
Business Contact:
BILLBOLT
() -
scorbett@abiomed.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): The overall objective of this proposed program is the commercialization of the Pediatric Impella system, a minimally invasive ventricular assist device (VAD) for treatment of acute heart failure in pediatric patients. T he device will be a less traumatic alternative to extracorporeal membrane oxygenation (ECMO), the current standard of care for these patients. The target patient population is in the age and weight range of 3 mos - 3 yrs and 5-15 kg. The Pediatric Impella system will be designed to unload the left ventricle and promote cardiac recovery, providing blood flow in the range of 0.5-2 lpm for up to 2 wks of support. Reviewers pointed out in discussion that the device is not as minimally invasive as claimed and wi ll require more anticoagulation than is suggested in the application. Since there are only a few devices in the field for this problem, this proposal addresses a great unmet clinical need and has high significance. PUBLIC HEALTH RELEVANCE: It is est imated that approximately 9,000 infants born with congenital heart defects each year in the U.S. require some form of invasive intervention during the first years of life. Many of these children require mechanical circulatory support as a bridge to recover y or to transplant. Shorter duration of support (for days to at most a few weeks) for acute, generally recoverable heart failure is mostly provided by extracorporeal membrane oxygenation (ECMO). ECMO is highly invasive and is associated with a host of comp lications including blood clots, bleeding, ongoing heart failure, and strokes. Therefore, a strong unmet clinical need exists for a minimally invasive ventricular assist device (VAD) that can supplant ECMO for treatment of acute heart failure in pediatric patients.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government